Type 2 Diabetes

Did you know that women with diabetes have a significantly higher risk of heart disease compared to men with diabetes? While many of the standard care guidelines apply to all patients, women often face additional, underrecognized threats to their heart and metabolic health. Understanding how sex-specific factors—such as hormonal changes, …

  As the burden of diabetic kidney disease (DKD) continues to grow, so does the urgency for early, evidence-based interventions. The concept of kidney protection diabetes is shifting—clinicians are now encouraged to initiate therapy before substantial kidney function loss occurs. Two major drug classes—SGLT2 inhibitors and GLP‑1 receptor agonists—are leading …

Could metabolic surgery be the turning point for your patients with type 2 diabetes who aren’t seeing results with medication alone? As evidence mounts around the success of metabolic surgery type 2 diabetes treatment, more clinicians are exploring when and how to refer patients. This guide explains who qualifies, what …

As diabetes technology advances, hybrid closed‑loop systems are no longer exclusive to type 1 diabetes. In recent years, their use in insulin-treated type 2 diabetes has gained attention. These systems promise better glucose control and improved quality of life by automating much of the insulin delivery process. But are they …

When managing type 2 diabetes, most decisions around treatment focus on blood sugar control and cardiovascular outcomes. But what about how patients feel day to day? The diabetes medications quality of life—including side effects like fatigue, gastrointestinal issues, and medication burden—often gets overlooked. Yet, these symptoms directly impact a patient’s …

Treating type 2 diabetes is no longer a one-size-fits-all endeavor. As new therapies emerge, clinicians face the ongoing challenge of selecting and sequencing medications in a way that balances efficacy, safety, cost, and patient preference. This comprehensive guide to type 2 diabetes drug sequencing outlines practical strategies for initiating, intensifying, …

As the demand for GLP‑1 receptor agonists skyrockets, clinics across the country are facing a critical question: How can we maintain quality care without overwhelming our teams? Rising interest in these therapies is placing new pressures on prescribing systems, patient education, and long-term follow-up. This article provides a clear, practical …

Managing diabetes in older adults isn’t just about adjusting medications—it’s about seeing the full picture of aging, frailty, and functionality. New 2025 standards highlight the need to assess frailty and functional status when setting A1C goals in elderly patients. But how do clinicians know when it’s time to de-intensify therapy …

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are still two of the most dangerous acute complications facing people with diabetes. However, a large portion of these cases can be prevented outside of the hospital. In 2025, the American Diabetes Association (ADA) released expanded guidance focused on DKA outpatient prevention, …

GLP‑1 receptor agonists and dual agonists like tirzepatide have become indispensable in managing type 2 diabetes and obesity. However, their effect on gastric emptying introduces specific risks during surgery that can’t be ignored. As their use grows, the need for clear, coordinated GLP‑1 perioperative management is more important than ever. …